Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

  1. Dorman, Klara
  2. Zhang, Danmei
  3. Heinrich, Kathrin
  4. Reeh, Laurens
  5. Weiss, Lena
  6. Haas, Michael
  7. Beyer, Georg
  8. Rössler, Daniel
  9. Goni, Elisabetta
  10. Renz, Bernhard W.
  11. D’Haese, Jan G.
  12. Kunz, Wolfgang G.
  13. Seidensticker, Max
  14. Corradini, Stefanie
  15. Niyazi, Maximilian
  16. Ormanns, Steffen
  17. Kumbrink, Jörg
  18. Jung, Andreas
  19. Klauschen, Frederick
  20. Werner, Jens
  21. Mayerle, Julia
  22. von Bergwelt-Baildon, Michael
  23. Boeck, Stefan
  24. Heinemann, Volker
  25. Westphalen, Benedikt ORCID logo

Download
s11523-023-00950-0.pdf 1,14MB
WeightNameValue
1000 Titel
  • Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
1000 Autor/in
  1. Dorman, Klara |
  2. Zhang, Danmei |
  3. Heinrich, Kathrin |
  4. Reeh, Laurens |
  5. Weiss, Lena |
  6. Haas, Michael |
  7. Beyer, Georg |
  8. Rössler, Daniel |
  9. Goni, Elisabetta |
  10. Renz, Bernhard W. |
  11. D’Haese, Jan G. |
  12. Kunz, Wolfgang G. |
  13. Seidensticker, Max |
  14. Corradini, Stefanie |
  15. Niyazi, Maximilian |
  16. Ormanns, Steffen |
  17. Kumbrink, Jörg |
  18. Jung, Andreas |
  19. Klauschen, Frederick |
  20. Werner, Jens |
  21. Mayerle, Julia |
  22. von Bergwelt-Baildon, Michael |
  23. Boeck, Stefan |
  24. Heinemann, Volker |
  25. Westphalen, Benedikt |
1000 Verlag
  • Springer International Publishing
1000 Erscheinungsjahr 2023
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-02-28
1000 Erschienen in
1000 Quellenangabe
  • 18(2):257-267
1000 Copyrightjahr
  • 2023
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s11523-023-00950-0 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042756/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!In pancreatic cancer, systemic treatment options in addition to chemotherapy remain scarce, and so far only a small proportion of patients benefit from targeted therapies.!##!Objective!#!The patients with pancreatic cancer discussed in the CCCMunich!##!Methods!#!Patients with pancreatic cancer who received comprehensive genomic profiling and were discussed in the interdisciplinary Molecular Tumor Board between May 2017 and July 2022 were included. These patients' medical charts, comprehensive genomic profiling results, and Molecular Tumor Board recommendations were analyzed in this retrospective cohort study.!##!Results!#!Molecular profiles of 165 patients with pancreatic cancer were discussed in the Molecular Tumor Board. In the 149 cases where comprehensive genomic profiling was successful, KRAS mutations were detected in 87.9%, TP53 in 53.0%, and CDKN2A in 14.1%. 33.3% of KRAS wild-type patients harbored targetable mutations, while these were only found in 19.1% of patients with the KRAS mutation; however, this difference was not statistically significant. 63.8% of patients with successful testing received a targeted treatment recommendation by the Molecular Tumor Board; however, only 3.2% of these were put into practice. Compared to a historic cohort of patients with pancreatic cancer with synchronous metastatic disease diagnosed between 2010 and 2017, the patients from the pancreatic cancer cohort with synchronous metastatic disease had a longer survival.!##!Conclusions!#!This single-center experience emphasizes the challenges of targeted treatment in pancreatic cancer. Very few patients ultimately received the recommended therapies, highlighting the need for more and better targeted treatment options in pancreatic cancer, early comprehensive genomic profiling to allow sufficient time to put Molecular Tumor Board recommendations into practice, and close cooperation with clinical trial units to give patients access to otherwise not available targeted treatments.
1000 Sacherschließung
lokal Pancreatic Neoplasms [MeSH]
lokal Pancreatic Neoplasms/genetics [MeSH]
lokal Medical and Health Sciences
lokal Mutation [MeSH]
lokal Humans [MeSH]
lokal Original Research Article
lokal Precision Medicine/methods [MeSH]
lokal Retrospective Studies [MeSH]
lokal Molecular Targeted Therapy/methods [MeSH]
lokal Pancreatic Neoplasms/drug therapy [MeSH]
lokal Proto-Oncogene Proteins p21(ras)/genetics [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/RG9ybWFuLCBLbGFyYQ==|https://frl.publisso.de/adhoc/uri/WmhhbmcsIERhbm1laQ==|https://frl.publisso.de/adhoc/uri/SGVpbnJpY2gsIEthdGhyaW4=|https://frl.publisso.de/adhoc/uri/UmVlaCwgTGF1cmVucw==|https://frl.publisso.de/adhoc/uri/V2Vpc3MsIExlbmE=|https://frl.publisso.de/adhoc/uri/SGFhcywgTWljaGFlbA==|https://frl.publisso.de/adhoc/uri/QmV5ZXIsIEdlb3Jn|https://frl.publisso.de/adhoc/uri/UsO2c3NsZXIsIERhbmllbA==|https://frl.publisso.de/adhoc/uri/R29uaSwgRWxpc2FiZXR0YQ==|https://frl.publisso.de/adhoc/uri/UmVueiwgQmVybmhhcmQgVy4=|https://frl.publisso.de/adhoc/uri/ROKAmUhhZXNlLCBKYW4gRy4=|https://frl.publisso.de/adhoc/uri/S3VueiwgV29sZmdhbmcgRy4=|https://frl.publisso.de/adhoc/uri/U2VpZGVuc3RpY2tlciwgTWF4|https://frl.publisso.de/adhoc/uri/Q29ycmFkaW5pLCBTdGVmYW5pZQ==|https://frl.publisso.de/adhoc/uri/Tml5YXppLCBNYXhpbWlsaWFu|https://frl.publisso.de/adhoc/uri/T3JtYW5ucywgU3RlZmZlbg==|https://frl.publisso.de/adhoc/uri/S3VtYnJpbmssIErDtnJn|https://frl.publisso.de/adhoc/uri/SnVuZywgQW5kcmVhcw==|https://frl.publisso.de/adhoc/uri/S2xhdXNjaGVuLCBGcmVkZXJpY2s=|https://frl.publisso.de/adhoc/uri/V2VybmVyLCBKZW5z|https://frl.publisso.de/adhoc/uri/TWF5ZXJsZSwgSnVsaWE=|https://frl.publisso.de/adhoc/uri/dm9uIEJlcmd3ZWx0LUJhaWxkb24sIE1pY2hhZWw=|https://frl.publisso.de/adhoc/uri/Qm9lY2ssIFN0ZWZhbg==|https://frl.publisso.de/adhoc/uri/SGVpbmVtYW5uLCBWb2xrZXI=|https://orcid.org/0000-0002-5310-3754
1000 Hinweis
  • DeepGreen-ID: fe5280734516408faec114ca5d1057ff ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6484965.rdf
1000 Erstellt am 2024-10-02T17:03:41.065+0200
1000 Erstellt von 322
1000 beschreibt frl:6484965
1000 Zuletzt bearbeitet 2024-10-04T16:05:16.900+0200
1000 Objekt bearb. Fri Oct 04 16:05:16 CEST 2024
1000 Vgl. frl:6484965
1000 Oai Id
  1. oai:frl.publisso.de:frl:6484965 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source